SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats by Hu, Weimin et al.
ORIGINAL BASIC RESEARCH Open Access
SMTP (Stachybotrys microspora triprenyl phenol)
enhances clot clearance in a pulmonary
embolism model in rats
Weimin Hu
1, Ritsuko Narasaki
1, Naoko Nishimura
2 and Keiji Hasumi
1,2*
Abstract
Background: Stachybotrys microspora triprenyl phenols (SMTPs) are a novel family of small molecules that enhance
both activation and fibrin-binding of plasminogen. While their effects on fibrinolysis have been characterized in
vitro, little is known about their activity in vivo with respect to plasminogen activation and blood clot clearance.
Results: To select a potent SMTP congener for the evaluation of its action in vitro and in vivo, we tested several
SMTP congeners with distinct structural properties for their effects on plasminogen activation. As a result, SMTP-7
(orniplabin) was found to have distinguished activity. Several lines of biochemical evidence supported the idea that
SMTP-7 acted as a plasminogen modulator. SMTP-7 elevated plasma level of plasmin-a2-antiplasmin complex, an
index of plasmin formation in vivo, 1.5-fold in mice after the intravenous injections at doses of 5 and 10 mg kg
-1.I n
a rat pulmonary embolism model, SMTP-7 (5 mg kg
-1) enhanced the rate of clot clearance ~3-fold in the absence
of exogenous plasminogen activator. Clot clearance was enhanced further by 5 mg kg
-1 of SMTP-7 in combination
with single-chain urokinase-type plasminogen activator.
Conclusions: Our results show that SMTP-7 is a superior plasminogen modulator among the SMTP family
compounds and suggest that the agent enhances plasmin generation in vivo, leading to clearance of thrombi in a
model of pulmonary embolism.
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Background
The plasminogen/plasmin system plays a central role in
blood clot lysis [1,2]. Plasminogen is a single-chain glyco-
protein consisting of an N-terminal PAN domain, five
homologous kringle domains, and a trypsin-like serine
protease domain. Plasminogen is converted to the active
enzyme plasmin by the specific cleavage of the Arg
561-
Val
562 bond by tissue-type plasminogen activator (t-PA)
or urokinase-type plasminogen activator (u-PA). The
binding of plasminogen to fibrin and cell surfaces,
mediated by kringle domains in plasminogen, localizes
fibrinolytic activity on fibrin and cell surfaces [3]. Plasmi-
nogen adopts a tight conformation due to an intramole-
cular interaction between a lysine residue (Lys
50 and/or
Lys
62) in the PAN domain and a lysine binding site in the
fifth kringle domain [4,5]. The tight conformation of the
plasminogen molecule attenuates its activation and inter-
action with fibrin and cellular receptors [3,6]. Lysine ana-
logs such as 6-aminohexanoic acid bind to lysine binding
sites in kringle domains and induce a large-scale confor-
mational change in plasminogen [7,8], facilitating its acti-
vation by plasminogen activators. However, lysine
analogs inhibit plasminogen binding to fibrin or cell sur-
face receptors and, therefore, inhibit fibrinolysis. Fibrin is
not only a substrate of plasmin but also a cofactor of
plasminogen activation. Upon binding to fibrin, plasmi-
nogen undergoes conformational change to become sus-
ceptible to activation [9]. Further, partial degradation of
fibrin by plasmin generates C-terminal lysines, resulting
in the accumulation of more plasminogen to degrading
fibrin to accelerate fibrinolysis. * Correspondence: hasumi@cc.tuat.ac.jp
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implicated in the localization and activation of plasmino-
gen. This mechanism suggests that pharmacological mod-
ulation of plasminogen conformation will regulate local
plasmin production [10]. We recently identified a series of
small-molecule modulators of plasminogen activation.
These compounds, which are structurally unrelated to
lysine, enhance plasminogen activator-catalyzed plasmino-
gen activation. Unlike lysine analogs, these modulators
increase plasminogen-fibrin binding [11]. SMTPs (Stachy-
botrys microspora triprenyl phenols) and staplabin are the
representatives of the “nonlysine-analog” plasminogen
modulators. [11-20]. In this paper, we show that SMTP-7
(orniplabin), one of the most potent congeners, increases
plasmin generation in vivo and promotes clot clearance in
a rat pulmonary embolism model. These activities provide
bases of the therapeutic activity of SMTP-7 toward throm-
botic cerebral infarction [21-23].
Results
Activities of the SMTP congeners in vitro
We assessed structure-activity relationships of SMTPs to
select a congener to be studied in detail. SMTP congeners
identified so far are roughly classified into two groups.
One is the single-unit congener, consisting of the core tri-
prenyl phenol unit and an N-linked side-chain, which is a
side-chain of an amino acid (Figure 1A). The other group
is the two-unit congener, consisting of two core units
bridged by a diamine (Figure 1A). Among the 8 congeners
tested, two-unit congeners (SMTP-7, -7D, -8, and -8D)
were more active than single-unit congeners (SMTP-4D,
-5D, -6, and -6D) in enhancing u-PA-catalyzed plasmino-
gen activation (Figure 1B). a-Tocopherol, which has a
structure resembling the core unit of SMTP (Figure 1A),
was inactive (Figure 1B). To characterize further, 3 addi-
tional two-unit congeners, SMTP-9, -30, and -31 (Figure
1A), were synthesized (additional file 1). SMTP-9 and -31,
which had two carboxyl groups, were less active than con-
geners with one carboxyl group (Figure 1B). SMTP-30,
which had no carboxyl group, was essentially inactive
(Figure 1B). Thus, the number of carboxyl group affects
the activity of two-unit SMTP congeners. Based on these
results, SMTP-7 was selected for detailed characterization.
Characterization of the action of SMTP-7 in vitro
SMTP-7 enhanced t-PA-catalyzed plasminogen activa-
tion as well as the activation catalyzed by u-PA (Figure
2A). In the kinetic determinations of u-PA-catalyzed
plasminogen activation, SMTP-7 markedly increased
Vmax and slightly decreased Km, resulting in a large
increase in kcat (Figure 2B). The increase in plasmin
generation was confirmed by SDS-polyacrylamide gel
electrophoresis (Figure 2C). Amidolytic activities of u-
PA and t-PA were not affected by SMTP-7 (Figure 2D).
While SMTP-7 moderately elevated the activity of plas-
min (Figure 2D), the magnitude (~3-fold) was smaller
than that of plasminogen activation (~100-fold). In size-
exclusion chromatography, the molecular elution time
of plasminogen was slightly shortened in the presence of
SMTP-7 (Figure 2E), suggesting that an increase in
apparent molecular volume was induced by SMTP-7.
Taken together, these properties of SMTP-7 are consis-
tent with the idea of a plasminogen modulator, which
increases plasminogen activation by affecting the confor-
mational status of plasminogen [10].
SMTP-7 increases plasma Pm-AP level in mice
To assess plasminogen activation in vivo, we determined
the level of Pm-AP as an index of plasmin generation.
Pm-AP was determined by fibrinogen zymography, in
which human and mouse Pm-AP appeared as lysis
bands at ~140 and ~130 kDa, respectively (additional
file 2). When SMTP-7 was administered to normal mice
(5 and 10 mg kg
-1, bolus intravenous injections), the
level of Pm-AP in plasma was significantly increased
(~1.5-fold, P < 0.05) (Figures 3A and 3B). Both anti-
plasminogen IgG and anti-a2-antiplasmin IgG decreased
the intensity of the lysis band, supporting that the lysis
band represented Pm-AP (Figure 3C and additional file
2). These results suggest that SMTP-7 enhances plasmin
generation in vivo.
SMTP-7 enhances clot clearance in a rat pulmonary
embolism model
SMTP-7 was evaluated further in a rat pulmonary
embolism model, in which animals were injected with
small particles of
125I-labeled plasma clots. The clots
predominantly distributed over the lungs, and its clear-
ance was monitored continually as the decay of radioac-
tivity in the thorax. Based on the effects of SMTP-7 on
the Pm-AP accumulation in mice (Figure 3), the dose of
5m gk g
-1 was used. In control animals given saline
alone, the clearance of
125I-plasma clots occurred slowly
(6.4 ± 2.8% per 20 min) (Figure 4A). The treatment with
SMTP-7 (5 mg kg
-1, bolus intravenous injection) signifi-
cantly increased the rate of clot clearance (19.8 ± 2.4%
per 20 min) (Figure 4A). This increase was comparable
to that (19.8 ± 4.1% per 20 min) brought by scu-PA
(250 U kg
-1, bolus intravenous injection) (Figure 4B).
The combination of SMTP-7 (5 mg kg
-1)a n ds c u - P A
(250 U kg
-1) increased the clot clearance rate to 42.3 ±
4.2% per 20 min (Figure 4B).
SMTP-7 does not increase bleeding in normal mice
Effects of SMTP-7 on bleeding and rebleeding were
assessed by a tail amputation assay in normal mice. SMTP-
7 was tested at the pharmacological dose (5 mg kg
-1)a n da
higher dose (30 mg kg
-1). Neither a statistically significant
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Page 2 of 9prolongation of bleeding time nor an increase in bleeding
volume was observed at both doses (additional file 3).
Discussion
In this study, we demonstrate that SMTP-7, one of the
two-unit SMTP congeners, is a plasminogen modulator
effective in plasminogen activation and clot clearance.
Among the SMTP congeners tested, the two-unit conge-
ners are more active than the single-unit congeners. Of
the two-unit congeners tested, analogs with two car-
boxylic acid groups in the N-linked side-chain are
weaker than those with one carboxylic acid group. The
analog with no carboxylic acid in the N-linked side-
chain is essentially inactive. Thus, the importance of
both the core triprenyl phenol unit and a carboxylic
acid group in the N-linked side-chain is demonstrated.
The action of SMTP-7 to enhance plasminogen activa-
tion conforms to the idea of zymogen modulators [10]
based on the following observations: (i) SMTP-7 does
not affect the enzymatic activity of u-PA and t-PA but
increases plasminogen activation catalyzed by u-PA and
t-PA; (ii) SMTP-7 alters conformational status of plas-
minogen, as evidenced by a change in molecular elution
time on analytical size-exclusion chromatography.
0 50 100 150 200 250 300
0
1
10
100
300
30
3
7
7D
8 8D
Toco
6 6D
4D
5D
Concentration ( M)
P
l
a
s
m
i
n
o
g
e
n
 
a
c
t
i
v
a
t
i
o
n
(
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
) 9
31
30
A 
B  Compound
 EC10
( M)
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Potency
(Emax/EC10, fold  M
-1)
SMTP-4D 167 29 0.17
SMTP-5D 181 28 0.15
SMTP-6 153 44 0.29
SMTP-6D 171 49 0.29
SMTP-7 65 102 1.56
SMTP-7D 74 156 2.11
SMTP-8 78 133 1.70
SMTP-8D 102 140 1.38
SMTP-9 179 66 0.37
SMTP-30 NAa 1
SMTP-31 NAa 6
-Tocopherol NAa 1
00 . 511 . 52
Figure 1 Structure-activity relationships of SMTP congeners. (A) Structures of SMTP congeners tested. The core unit of SMTP congeners is
represented by R. (B) The activation of plasminogen was assayed in the presence of the indicated concentrations of SMTP congeners. Number
in circle represents the SMTP number. Toco, a-tocopherol. Each value represents the mean ± SD from triplicate determinations. Relative to
control values are shown. Summary of the results are shown in the right panel, where EC10 represents the concentration (μM) of SMTP that
causes 10-fold enhancement of plasminogen activation and Emax the maximum level of the enhancement (fold increase in plasminogen
activation compared with control). Emax and the reciprocal of EC10 are independent indexes that represent the potency of the compound. The
ratio Emax/EC10 represents comprehensive potency. NA, not available (due to that enhancement did not reach 10-fold at concentrations tested).
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two-chain plasmin. This activity, along with the aug-
mentation of the catalytic activity of plasmin (~3-fold),
results in the apparent increase (up to 100-fold) in plas-
minogen activation assessed by using a chromogenic
substrate. Kinetic data demonstrate that SMTP-7
increases Vmax of u-PA-catalyzed plasminogen activation
with a slight decrease in Km, suggesting that faster turn-
over of the enzyme is allowed on the SMTP-7-modu-
lated substrate compared with a native substrate.
The administration of SMTP-7 to normal mice resulted
in an increase in the level of Pm-AP in plasma. Since plas-
min generated in vivo is rapidly inactivated by a2-antiplas-
min to afford Pm-AP, the level of Pm-AP represents the
generation of plasmin in vivo [24]. SMTP-7 does not affect
the rate of Pm-AP formation when plasmin is incubated
with a2-antiplasmin in a purified system (unpublished
observation). Thus, the finding that SMTP-7 increases
plasma level of Pm-AP in mice suggests that SMTP-7
increases plasminogen activation in vivo. SMTP-7 is effec-
tive in promoting the clot clearance in the rat pulmonary
embolism model. Compared with the spontaneous clot
clearance rate, a 3-fold increase in the rate is brought by
the administration of SMTP-7 at 5 mg kg
-1, a dose that is
effective in elevating plasma Pm-AP level. The plasma
concentration of SMTP-7 at this dose just after the intra-
venous injection is expected to be ~100 μM. The rate of
clot clearance after the SMTP-7 injection is comparable to
the rate brought by the injection of scu-PA at 250 U kg
-1.
SMTP-7 synergistically enhances the clot clearance in
combination with scu-PA. Thus, these properties of the
SMTP-7 action in vivo conform to its activity in vitro.
A B C 
E  D 
Figure 2 Characterization of SMTP-7 in vitro. (A) Effects on plasminogen activation by t-PA and u-PA. Plasminogen activation was assayed
using t-PA or u-PA in the presence of the indicated concentrations of SMTP-7. (B) Kinetic measurements of u-PA-catalyzed plasminogen
activation in the presence of SMTP-7 (100 μM). Parameters shown were obtained from triplicate determinations. (C) Effect on plasminogen
conversion to plasmin. u-PA-catalyzed
125I-plasminogen conversion to plasmin was assayed in the presence or absence of SMTP-7 (100 μM).
Positions of plasminogen (Plg) and A- and B-chains of plasmin are shown. (D) Effects on amidolytic activities of plasmin, t-PA, and u-PA. Activity
of each enzyme was determined using a fluorogenic substrate in the presence of the indicated concentrations of SMTP-7. (E) Size-exclusion
chromatography. Alexa 488-labeled plasminogen was eluted in the absence or presence of SMTP-7 (120 μM). **, P < 0.05 by Student’s t-test.
Error bars in panels A, B, D, and E represent SD from triplicate determinations.
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hyperfibrinolysis and following hemorrhage as that
observed in disseminated intravascular coagulation.
However, our preliminary studies suggest that these are
unlikely to occur at a pharmacological dose (<10 mg/
kg), since bleeding time and rebleeding volume in a
m o u s et a i la m p u t a t i o na s s a yw e r en o tc h a n g e ds t a t i s t i -
c a l l yb yt h eS M T P - 7a d m i n i s t r a t i o na tt h ep h a r m a c o l o -
gical dose (5 mg kg
-1)a n dah i g h e rd o s e( 3 0m gk g
-1)
(additional file 3). This moderate effect of SMTP-7 on
hemorrhage can be explained by that SMTP-7 is a
zymogen modulator and its action depends on endogen-
ous plasminogen activators, the availability of which is
physiologically regulated.
Plasminogen activators such as recombinant t-PA are
important drugs treating acute thrombotic stroke and
myocardial infarction [25,26]. Recent investigations have
demonstrated that SMTP-7 is quite effective in amelior-
ating thrombotic stroke in models of mouse and gerbil
[21-23]. The data in this paper provide bases of the
therapeutic activity of SMTP-7 in these models. It is of
note that SMTP-7 is effective in the treatment after 3-6
h of the thrombotic stroke induction, whereas t-PA is
ineffective when treated after 3 h [21,22]. The difference
in the therapeutic efficacy between SMTP-7 and t-PA is
partly explained as that SMTP-7 reduces inflammatory
and oxidative responses associated with thrombotic
ischemia [22,23,27]. t-PA is reported to induce cerebral
inflammation and neuronal cell death by directly inter-
acting with low density lipoprotein receptor-related pro-
tein and N-methyl-D-aspartate receptor [28,29]. In
consistent with these observations, hemorrhagic trans-
formation is reduced by SMTP-7, while it is increased
by t-PA [22]. Thus, SMTP-7 can be a unique agent that
aid in the treatment of thrombotic complications.
Conclusion
Our results show that SMTP-7 is a superior plasmino-
gen modulator among the SMTP family compounds and
suggest that the agent enhances plasmin generation in
vivo, leading to clearance of thrombi in a model of pul-
monary embolism. These results provide mechanistic
bases for the recent findings that SMTP-7 has a pro-
found activity in treating thrombotic stroke in animal
models.
Methods
Materials
Human native plasminogen was isolated by lysine-
Sepharose affinity chromatography from frozen citrated
plasma. The source of the following reagents were: sin-
gle-chain u-PA (scu-PA; Thrombolyse
®)f r o mM i t s u -
bishi Pharma (Osaka, Japan); high molecular weight u-
PA (1.47 × 10
5 IU mg
-1) from JCR Pharmaceuticals
(Kobe, Japan); two-chain t-PA (7.0 × 10
5 IU mg
-1)f r o m
Biopool (Umeå, Sweden); sheep anti-mouse plasminogen
A 
C 
130 
kDa 
130 
kDa 
B 
Figure 3 Effect of SMTP-7 on plasma level of Pm-AP in normal mice. Mice were intravenously injected with SMTP-7 at a bolus dose of 5
mg kg
-1 (n =5 )o r1 0m gk g
-1 (n = 5). After 60 min, blood was drawn to determine Pm-AP levels in plasma by fibrinogen zymography. Control
animals (n = 5) received saline. (A) Representative zymogram. Plasmas from 5 animals in each group were combined and aliquots (2 μl) of the
mixtures were subjected to zymography. Human Pm-AP (hPm-AP, 1.7 ng) was resolved as the standard. (B) The summary of the quantification of
Pm-AP. Plasma (2 μl) from each of the five mice was independently subjected to zymographic analysis. Data were calibrated by comparing the
intensity of each lysis band with that of the standard human Pm-AP. The mean + SD of the data obtained from each animal is shown. *, P <
0.05 and **, P < 0.01 compared with control by the Dunnett’s multiple comparison test. (C) Authenticity confirmation. The mixture of plasma in
the 5 mg kg
-1 SMTP-7 group was treated with anti-plasminogen IgG (Anti-Plg), anti-a2-antiplasmin IgG (Anti-AP), or buffer before the
zymographic determination of Pm-AP.
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Page 5 of 9IgG from Haematologic Technologies (Essex Junction,
VT, USA); rabbit anti-mouse a2-antiplasmin IgG from
Merdian Life Science (Saco, ME, USA); human fibrino-
gen and human a-thrombin from Sigma (St. Louis, MO,
USA); carrier-free Na
125If r o mA m e r s h a m .R a d i o i o d i n a -
tion of fibrinogen and plasminogen was performed
using the iodine monochloride method. Upon trichlor-
oacetic acid treatment, more than 95% of radioactivity
in the fibrinogen and plasminogen preparations precipi-
tated with protein. When treated with thrombin,
approximately 70% of the radioactivity in
125I-fibrinogen
was incorporated into the resulting clots.
SMTP congeners
All the SMTP congeners used in this study were pro-
duced by S. microspora IFO 30018. SMTP-4D, -5D, -6,
-6D, -7, -7D, -8, and -8D were isolated as described pre-
viously [15,17]. SMTP-9, -30, and -31 were originally
isolated as described in additional file 1. In experiments
in vitro, SMTPs were dissolved directly in buffer A (50
mM Tris-HCl, 100 mM NaCl, and 0.01% Tween 80, pH
7.4). In animal experiments,S M T P - 7w a sd i s s o l v e di n
saline by adjusting pH ~9 with dilute NaOH.
Assay for plasminogen activation
Plasminogen activation was determined by measuring
the initial velocity of plasmin generation using H-Val-
Leu-Lys-p-nitroanilide (Bachem, Bubendorf, Switzer-
land), a chromogenic substrate for plasmin. A reaction
mixture consisting of 50 nM plasminogen, 50 IU ml
-1 u-
PA (or 200 IU ml
-1 t - P A )a n d0 . 1m Mo ft h es u b s t r a t e
in 50 μl of buffer A was incubated in a well of a 96-well
** 
** 
A 
B 
Figure 4 Effect of SMTP-7 on clot clearance in a rat pulmonary embolism model. Rats were injected intravenously with
125I-labeled plasma
clots. The clearance of the clots was monitored before and after the treatments with SMTP-7 and/or scu-PA. (A) SMTP-7 (5 mg kg
-1; n = 6) was
administered intravenously ~20 min after the injection of
125I-labeled plasma clot. Control animals (n = 6) received saline. Radioactivity over the
thorax was monitored (one of the 6 traces is shown in the left panel) and the fractional change in radioactivity was summarized (right panel). (B)
SMTP-7 (5 mg kg
-1), followed by 250 U kg
-1 of scu-PA (Thrombolyse
®), was administered intravenously ~20 min after the clot injection (n = 6).
One unit of Thrombolyse
® is comparable to ~60 IU of tcu-PA in fibrinolytic activity. In control animals (n = 6), scu-PA was given ~20 min after
the clot injection. Arrow denotes time at which the administration was made. **, P < 0.01 compared with control by the Student’s t-test with
normally distributed variables.
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Page 6 of 9microplate at 37°C for up to 40 min. Absorbance at 405
nm was measured with an interval of 1 to 2 min. From
the slope of the plots of A405 nm versus t
2, the initial
velocity of plasmin generation was calculated. In the
experiment to determine kinetic parameters, assays were
performed with varying concentrations of plasminogen
(0.5-2 μM) and a fixed concentration of u-PA (50 IU
ml
-1) in the presence or absence of SMTP-7 (100 μM).
Since SMTP-7 at 100 μM enhanced plasmin activity
toward H-Val-Leu-Lys-p-nitroanilide by 3.26-fold (see
Figure 2D), this factor was taken into account in the
process of the calculation of plasmin generation
velocities.
Plasminogen activation was alternatively assayed by
determining the conversion to the two-chain form.
125I-
Plasminogen (100 nM) was incubated with u-PA (50 IU
ml
-1) and aprotinin (100 kallikrein inhibitor units ml
-1)
in buffer A at 37°C for 30 min. The mixture was
resolved on SDS-polyacrylamide gel electrophoresis
under reducing conditions. The gel was stained with
Coomassie Brilliant Blue R-250.
Assay for activities of plasmin, u-PA, and t-PA
Amidolytic activities of plasmin (10 nM), u-PA (1 IU
ml
-1), and t-PA (2000 IU ml
-1) were determined at 37°C
in buffer A using 10 μM of H-Val-Leu-Lys-7-amino-4-
methylcoumarin, t-butyloxycarbonyl-Glu-Gly-Arg-7-
amino-4-methylcoumarin, and succinyl-Phe-Ser-Arg-7-
amino-4-methylcoumarin, respectively.
Size-exclusion chromatography
Size-exclusion chromatography was performed using a
TSK-Gel G-3000SW column (7.5 × 600 mm, TOSOH,
Tokyo, Japan) equilibrated with buffer A in the presence
o ra b s e n c eo fS M T P - 7( 1 2 0μM). Plasminogen labeled
with Alexa Fluor
® 488 (Molecular Probes, Eugene, OR,
USA) (10 μg) was resolved at room temperature at a
rate of 1 ml/min. The elution was monitored using a
fluorescence detector with an excitation at 495 nm and
an emission at 520 nm.
Animal Experiments
All of the animal protocols were approved by the insti-
tutional animal care committee of Tokyo Noko Univer-
sity. Male Wistar rats and male ICR mice were obtained
from Japan SLC (Hamamatsu).
Determination of plasmin-a2-antiplasmin complex (Pm-
AP)
Male ICR mice (7 weeks of age) received intravenous
SMTP-7 or saline. After 60 min, blood was collected
from inferior vena cava in 13 mM sodium citrate.
Plasma was rapidly prepared by centrifugation and
mixed with one volume of buffer B (125 mM Tris-HCl,
pH 6.8, 4% (w/v) SDS, 20% (w/v) glycerol, and 0.004%
(w/v) bromophenol blue). In some experiments, plasma
was pretreated with ant-plasminogen IgG (0.6 mg ml
-1)
or anti-a2-antiplasmin IgG (3 mg ml
-1)f o r3 0m i na t
room temperature before mixing with buffer B. The
mixture (equivalent to 1-2 μl of plasma) was resolved on
nonreduced SDS-polyacrylamide gel electrophoresis on a
7.5% gel containing fibrinogen (2 mg ml
-1)a t4 ° C .A s
the standard for the calibration of Pm-AP in plasma
samples, 1.7 ng of human Pm-AP (prepared by incubat-
ing 120 nM human plasmin and 600 nM human a2-
antiplasmin for 30 min at 37°C in buffer A) was resolved
on the same gel. After electrophoresis, the gel was cut at
the position of ~90 kDa, and the upper half was washed
with Triton X-100 (2.5 %, w/v) and incubated in 50 mM
Tris-HCl, pH 8.3, and 100 mM glycine for 60 h at 37°C.
(The lower half gave a strong lysis band at ~70 kDa,
possibly due to plasma kallikrein) Gels were stained
with Coomassie Brilliant Blue R-250. The lysis zones
due to protease activities appeared as unstained bands
on a blue background. Human Pm-AP gave a lysis band
at ~140 kDa, while the mouse counterpart afforded a
band at ~130 kDa (additional file 2). The scanned image
of the stained gel was reversed for presentations. The
band intensity was determined using Scion image. The
amounts of Pm-AP in test samples were calibrated by
comparing intensities of lysis bands of samples with that
of the standard, and data were expressed as human Pm-
AP equivalent (nM in plasma).
Preparation of
125I-plasma clot particles
Platelet-poor plasma from male Wistar rats was mixed
with
125I-fibrinogen (139 μgm l
-1,~ 2 . 5M B q )a n da-
thrombin (1 IU ml
-1) in the presence of 44 mM CaCl2.
After incubation at 37°C for 120 min, the resulting
plasma clot was washed thrice with saline and powdered
in a mortar under liquid nitrogen, followed by homoge-
nization 4 strokes in 2.7 ml saline using a Potter Elveh-
jem homogenizer with a Teflon pestle (13-mm in
diameter). The suspension was left at room temperature
for 30 min, and the resulting precipitates were homoge-
nized again. This operation was repeated once more.
The combined homogenates were settled for 30 min,
and the resulting supernatant was centrifuged at 20 × g
for 3 min to obtain pellet consisting of clot particles of
10-100 μm in diameter.
Measurement of clot clearance in the lungs
Male Wistar rats weighing ~120 g were kept at 22°C
with normal chaw for 1-7 days before the use in experi-
ments. Rats were anesthetized with urethane and chlora-
lose (750 and 65 mg kg
-1, respectively, i.p.), and a probe
(equipped with a 10-mm collimator) of a model TCS-
163 NaI scintillation survey monitor (Aloka, Tokyo,
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Page 7 of 9Japan) was placed above the thorax. A suspension of
125I-plasma clot particles (75 μlk g
-1;~ 1 . 2×1 0
7 Bq per
animal) was injected simultaneously with heparin (165
units kg
-1) and NaI (3.3 mg kg
-1) into a caudal vein. The
125I-plasma clots predominantly distributed over the
lungs [30], and radioactivity over the thorax was mea-
sured continually. Saline alone (0.5 ml per animal), saline
containing SMTP-7 (5 mg kg
-1), scu-PA (250 U kg
-1), or
both SMTP-7 and scu-PA was intravenously injected ~20
min after the embolization. The monitoring of radioactiv-
ity was continued further for ~20 min. The fractional
change in radioactivity during 20 min after the treat-
ments represented the rate of clot dissolution.
Bleeding and rebleeding in mice
The measurement of bleeding time and rebleeding
volume (secondary oozing from the bleeding time
wounds) were performed using male ICR mice (6 weeks
of age) as described previously [31]. Briefly, mice were
anesthetized with 60 mg kg
-1 pentobarbital intraperito-
neally and given bolus injection of 5% mannitol (5 ml
kg
-1) or SMTP-7 (5 and 30 mg kg
-1)i n5 %m a n n i t o lvia
a tail vein. Five minutes after the administration, a 5-
mm tail segment was amputated with a razor blade. The
tail was immersed immediately in prewarmed saline at
37°C, and the time required to stop visual spontaneous
bleeding was determined. To evaluate rebleeding, the
tail was then immersed in another 4-mL prewarmed sal-
ine (37°C) containing 14 mM trisodium citrate for 60
min. Red blood cells were collected and lysed in water
to measure absorbance at 490 nm, from which blood
loss by rebleeding was calculated.
Additional material
Additional file 1: Supplementary Methods and Supplementary
Table 1.
Additional file 2: Supplementary Figure 1: The bases of the
quantification of Pm-AP and the confirmation of its authenticity. (A)
Human Pm-AP (hPm-AP) was resolved on a SDS-polyacrylamide gel
containing 2 mg ml
-1 human fibrinogen and processed for detection of
lysis band. The plotted data are the average of duplicate determinations.
The intensity of the lysis bands at ~140 kDa was proportional to the
amount of hPm-AP at 0.1-3 ng (r = 0.99). (B) Mouse citrated plasma was
recalcified (20 mM CaCl2) for 16 h at room temperature to induce Pm-AP
formation. After centrifugation, the resulting supernatant (5 μl) was
mixed for 30 min with 0.6 μgm l
-1 of anti-plasminogen IgG (Anti-Plg)o r
anti-a2-antiplasmin IgG (Anti-AP). After incubation for 30 min at room
temperature, supernatant of the sample (equivalent to 2 μl of the
original plasma) was resolved on a SDS-polyacrylamide gel containing 2
mg ml
-1 casein for zymography. The intensity of the lysis band at ~130
kDa was decreased by the treatments with anti-plasminogen IgG and
anti-a2-antiplasmin IgG, demonstrating the authenticity of the ~130 kDa
lysis band as Pm-AP. Similar results were obtained when samples were
processed for zymography after removal of the immune complexes with
protein G-Sepharose. (It is likely that the immune complexes precipitate
following the reaction or that the IgG binding prevents the regeneration
of plasmin activity during the zymography process.)
Additional file 3: Supplementary Figure 2: Bleeding and rebleeding
following SMTP-7 administration in mice. (A) Bleeding time in mice
was determined after an intravenous administration of 5% mannitol
(Control) or SMTP-7 (5 and 30 mg kg
-1) dissolved in the vehicle. (B)
Following the determination of bleeding time, the mice were subjected
to the measurement of rebleeding. The mean + SD (n = 7 for control
and 5 mg kg
-1 groups and n = 5 for 30 mg kg
-1 group) was shown.
There was no statistical difference between any groups with respect to
both bleeding time and rebleeding volume as assessed by the Tukey-
Kramer test.
List of abbreviations
t-PA: tissue-type plasminogen activator; u-PA: urokinase-type plasminogen
activator; scu-PA: single-chain urokinase-type plasminogen activator; Pm-AP:
plasmin-α2-antiplasmin complex.
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